OA06.03 Patient-Reported Outcomes from ADAURA: Osimertinib as Adjuvant Therapy in Patients with Resected EGFR Mutated (EGFRm) NSCLC

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 16; no. 3; pp. S112 - S113
Main Authors Majem, M., Goldman, J., John, T., Grohe, C., Laktionov, K.K., Kim, S., Kato, T., Vu, H.V., Lu, S., Lee, K.Y., Akewanlop, C., Yu, C., De Marinis, F., Bonanno, L., Domine, M., Shepherd, F., Zeng, L., Kulkarni, D., Medic, N., Tsuboi, M., Herbst, R., Wu, Y.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.03.2021
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
1556-1380
DOI:10.1016/j.jtho.2021.01.291